Running with scissors: Using antiretroviral therapy without monitoring viral load

Clinical Infectious Diseases

Volumn 46, Issue 10, 2008, Pages 1598-1600

  Smith, Davey M ^a   Schooley, Robert T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; GENOTYPE; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE SYSTEM; NOTE; PHENOTYPE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RNA REPLICATION; TREATMENT FAILURE; VIRUS LOAD; WORLD HEALTH ORGANIZATION; ANTIVIRAL RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; TREATMENT OUTCOME; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 43249114872     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587110     Document Type: Note

References (48)

1. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 revision. 2004. Available at: http://www.who.int/3by5/publications/ en. Accessed 3 January 2008.
2. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185-91.
3. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-4.
4. Schooley RT, Ramirez-Ronda C, Lange JM, et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996; 173:1354-66.
5. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996; 276:118-25.
6. Gulick RM. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-9.
7. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA 1998; 279:930-7.
8. Gulick RM. 3-Year suppression of HIV viremia with indinavir, zidovudine and lamivudine. Ann Intern Med 2000; 133:35-9.
9. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997; 94:12574-9.
10. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996; 276:1955-6.
11. Durant J. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt study. AIDS 2000; 14:1333-9.
12. Robertson SM, Penzak SR, Pau A. Drug interactions in the management of HIV infection: an update. Expert Opin Pharmacother 2007; 8:2947-63.
13. Paris D, Ledergerber B, Weber R, et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999; 15:1631-8.
14. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
15. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
16. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-43.
17. Hornberger J, Holodniy M, Robertus K, Winnike M, Gibson E, Verhulst E. A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. Med Decis Making 2007; 27:789-821.
18. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134:440-50.
19. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
20. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44:990-7.
21. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-9.
22. Kimmel AD, Goldie SJ, Walensky RP, et al. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther 2005; 10:41-52.
23. Freedberg KA, Kumarasamy N, Losina E, et al. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 2007; 21(Suppl 4):S117-28.
24. Wolf LL, Ricketts P, Freedberg KA, et al. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean. J Acquir Immune Defic Syndr 2007; 46:463-71.
25. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med 2006; 355:1141-53.
26. STEP study: disappointing, but not a failure. Lancet 2007; 370:1665.
27. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-97 (in this issue)
28. Weidle PJ, Downing R, Sozi C, et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative - Uganda. AIDS 2003; 17(Suppl 3):S39-48.
29. Spacek LA, Shihab HM, Kamya MR, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006; 42:252-9.
30. Rodrigues R, Custodio RM, Bueno SM, et al. Prevalence of ARV resistance mutations and impact of genotyping test in HIV patients with advance disease in Sao Paulo, Brazil. J Clin Virol 2005; 32:336-7.
31. Seyler C, Adje-Toure C, Messou E, et al. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 2007; 21:1157-64.
32. Harrigan PR, Montaner JS, Wegner SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15:1671-7.
33. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19:1-7.
34. Shaw GM, Hahn BH, Arya SK, Groopman JE, Gallo RC, Wong-Staal F. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 1984; 226:1165-71.
35. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5.
36. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
37. Richman DD. HIV chemotherapy. Nature 2001; 410:995-1001.
38. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20:W13-23.
39. Wainberg MA. HIV-1 subtype distribution and the problem of drug resistance. AIDS 2004; 18(Suppl 3):S63-8.
40. Pillay D, Walker AS, Gibb DM, et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002; 186:617-25.
41. Gupta RK, Pillay D. HIV resistance and the developing world. Int J Antimicrob Agents 2007; 29:510-7.
42. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2:e112.
43. Bagchi S, Kempf MC, Westfall AO, Maherya A, Willig J, Saag MS. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis 2007; 44:135-8.
44. Garcia R, Badaro R, Netto EM, et al. Cross-sectional study to evaluate factors associated with adherence to antiretroviral therapy by Brazilian HIV-infected patients. AIDS Res Hum Retroviruses 2006; 22:1248-52.
45. Freedberg KA, Scharfstein JA, Seage III GR, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279:130-6.
46. Vijayaraghavan A, Efrusy MB, Mazonson PD, Ebrahim O, Sanne IM, Santas CC. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr 2007; 46:91-100.
47. Fiscus SA, Cheng B, Crowe SM, et al. HIV-1 viral load assays for resource-limited settings. PLoS Med 2006; 3:e417.
48. Santayana G. The life of reason; or, the phases of human progress. New York: C. Scribner's Sons, 1905.